https://pharmatlas.org/ 2026-04-06T06:09:24+00:00 https://pharmatlas.org/ https://pharmatlas.org/lib/exe/fetch.php?media=logo.png text/html 2026-03-15T17:02:36+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=cardio:diuretics:acetazolamide&rev=1773594156&do=diff ====== Acetazolamide (Diamox®) ====== | | |^ Acetazolamide || Brand Names | Diamox® || Drug Class | Carbonic Anhydrase Inhibitor || Primary Indications | Glaucoma; Altitude sickness; Metabolic alkalosis; Idiopathic intracranial hypertension || Blood Pressure Effect | Mild ↓ BP || Mortality Benefit | No || Elimination | Renal || Black Box Warning | No || FDA Approval | 1954 | text/html 2026-03-15T17:05:04+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=cardio:diuretics:bumetanide&rev=1773594304&do=diff ====== Bumetanide (Bumex®) ====== | | |^ Bumetanide || Brand Names | Bumex® || Drug Class | Loop Diuretic || Primary Indications | Heart Failure; Edema; CKD volume overload || Blood Pressure Effect | ↓ preload, ↓ BP || Mortality Benefit | No (symptom relief) || Elimination | Hepatic & renal || Black Box Warning | Ototoxicity (high dose/rapid IV) || FDA Approval | 1983 | text/html 2026-03-15T17:05:10+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=cardio:diuretics:chlorthalidone&rev=1773594310&do=diff ====== Chlorthalidone (Hygroton®) ====== | | |^ Chlorthalidone || Brand Names | Hygroton® || Drug Class | Thiazide-Like Diuretic || Primary Indications | Hypertension; Edema || Blood Pressure Effect | ↓ BP (chronic) || Mortality Benefit | No (BP control) || Elimination | Renal || Black Box Warning | No || FDA Approval | 1960 | text/html 2026-03-15T17:02:42+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=cardio:diuretics:furosemide&rev=1773594162&do=diff ====== Furosemide (Lasix®) ====== | | |^ Furosemide || Brand Names | Lasix® || Drug Class | Loop Diuretic || Primary Indications | Heart Failure; Pulmonary edema; Volume overload; CKD edema || Blood Pressure Effect | ↓ preload, ↓ BP || Mortality Benefit | No (symptom relief) || Elimination | Renal || Black Box Warning | Ototoxicity (high dose/rapid IV) || FDA Approval | 1966 | text/html 2026-03-15T17:02:47+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=cardio:diuretics:hydrochlorothiazide&rev=1773594167&do=diff ====== Hydrochlorothiazide (HCTZ®) ====== | | |^ Hydrochlorothiazide || Brand Names | HCTZ® || Drug Class | Thiazide Diuretic || Primary Indications | Hypertension; Mild edema || Blood Pressure Effect | ↓ BP (chronic) || Mortality Benefit | No (BP control) || Elimination | Renal || Black Box Warning | No || FDA Approval | 1959 | text/html 2026-02-13T01:28:06+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=cardio:diuretics:mra&rev=1770946086&do=diff Potassium-Sparing Diuretics Potassium-sparing diuretics act at the collecting duct. They reduce sodium reabsorption while preserving potassium. These agents have weak diuretic effect but important clinical roles. Used in: * Heart Failure * Resistant Hypertension * text/html 2026-02-15T03:28:00+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=cardio:diuretics:start&rev=1771126080&do=diff Diuretics Diuretics alter renal sodium handling to reduce extracellular volume. Because water follows sodium, altering sodium reabsorption changes: * Blood volume * Preload * Blood pressure * Edema Diuretics are foundational in: * Hypertension * text/html 2026-03-15T17:04:59+00:00 Anonymous (anonymous@undisclosed.example.com) https://pharmatlas.org/doku.php?id=cardio:diuretics:torsemide&rev=1773594299&do=diff ====== Torsemide (Demadex®) ====== | | |^ Torsemide || Brand Names | Demadex® || Drug Class | Loop Diuretic || Primary Indications | Heart Failure; Edema; Hypertension (selected) || Blood Pressure Effect | ↓ preload, ↓ BP || Mortality Benefit | No (symptom relief) || Elimination | Hepatic & renal || Black Box Warning | Ototoxicity (high dose/rapid IV) || FDA Approval | 1993 |